Grail (NASDAQ:GRAL) Trading Down 6.6% – Should You Sell?

Grail, Inc. (NASDAQ:GRAL) traded down 6.6% during trading on Friday . The stock traded as low as $42.00 and last traded at $44.60. 558,219 shares were traded during trading, a decline of 61% from the average session volume of 1,429,129 shares. The stock had previously closed at $47.76.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Morgan Stanley assumed coverage on shares of Grail in a research note on Wednesday, November 27th. They set an “equal weight” rating and a $16.00 price objective for the company. Wolfe Research assumed coverage on shares of Grail in a research note on Friday, November 15th. They set a “peer perform” rating for the company.

Grail Stock Performance

The firm’s 50 day moving average is $26.69 and its 200 day moving average is $19.22.

Grail (NASDAQ:GRAL) last released its earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share for the quarter, topping the consensus estimate of ($4.41) by $2.55. The company had revenue of $38.25 million for the quarter, compared to analysts’ expectations of $35.33 million. On average, analysts forecast that Grail, Inc. will post -15.15 earnings per share for the current year.

Institutional Trading of Grail

Large investors have recently bought and sold shares of the stock. FNY Investment Advisers LLC purchased a new stake in Grail during the 4th quarter worth approximately $26,000. Lindbrook Capital LLC purchased a new stake in Grail during the 4th quarter worth approximately $28,000. State of Tennessee Department of Treasury purchased a new stake in Grail during the 4th quarter worth approximately $28,000. Sterling Capital Management LLC purchased a new stake in Grail during the 4th quarter worth approximately $29,000. Finally, Wellington Shields Capital Management LLC purchased a new stake in Grail during the 4th quarter worth approximately $33,000.

Grail Company Profile

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.